887128-72-5

Basic information

• Product Name: {3-(4-chloro-phenyl)-3-[(4-oxo-3,4-dihydro-quinazoline-7-carbonyl)-amino]-propyl}-carbamic acid benzyl ester
• Synonyms: {3-(4-chloro-phenyl)-3-[(4-oxo-3,4-dihydro-quinazoline-7-carbonyl)-amino]-propyl}-carbamic acid benzyl ester
• CAS NO: 887128-72-5
• Molecular Weight: 490.946
• Mol File: 887128-72-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: {3-(4-chloro-phenyl)-3-[(4-oxo-3,4-dihydro-quinazoline-7-carbonyl)-amino]-propyl}-carbamic acid benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: {3-(4-chloro-phenyl)-3-[(4-oxo-3,4-dihydro-quinazoline-7-carbonyl)-amino]-propyl}-carbamic acid benzyl ester(887128-72-5)
• EPA Substance Registry System: {3-(4-chloro-phenyl)-3-[(4-oxo-3,4-dihydro-quinazoline-7-carbonyl)-amino]-propyl}-carbamic acid benzyl ester(887128-72-5)

Safety Data

• Hazardous Substances Data: 887128-72-5(Hazardous Substances Data)

Upstream product

• 887194-24-3 [3-amino-3-(4-chloro-phenyl)-propyl]-carbamic acid benzyl ester 
• 202197-73-7 4-oxo-3,4-dihydroquinazoline-7-carboxylic acid 

Relevant articles and documents

PHARMACEUTICAL COMPOUNDS

The invention provides a compound of the formula (I) or a salt, solvate, tautomer or N-oxide thereof for use in the treatment or prophylaxis of a disease state or condition mediated by protein kinase A and/or protein kinase B, wherein the ring Q is a benzene ring; J2-J1 is N=CR7 or R1aN-CO; G is OH or NR5R6; E is CONR7, NR7CO, C(R8)=C(R8) or (X)m(CR8R8a)n where X is O, S or NR7; provided that when J2-J1 is R1aN-CO, E is other than NR7CO; m and n are each 0 or 1, where m + n = 1 or 2; A is a bond and R4 and R4a are absent, or A is a saturated optionally substituted C1-7 hydrocarbon linker group having a maximum chain length of 5 atoms extending between E and G, one carbon atom in the linker group A being optionally replaced by O or N; R1,Rla, R2, and R3 are each H; halogen; C1-6 hydrocarbyl optionally substituted by halogen, OH or C1-2 alkoxy; CN; CONHR8; NH2; NHCOR10 or NHCONHR10; R4 is H or C1-4 alkyl; R4a is H, C1-4 alkyl or a group R9; R5 and R6 are each selected from H, R9 and C1-4 hydrocarbyl optionally substituted by halogen, C1-2 alkoxy or R9;or NR5R6 forms a saturated 4-7 membered monocyclic heterocyclic group; R7 is H or C1-4 alkyl; R8 and R8a each H or saturated C1-4 hydrocarbyl optionally substituted by fluorine; R9is a monocyclic or bicyclic carbocyclic or heterocyclic group containing up to 3 ring heteroatoms selected from N, O and S; or R4, R4a and A together form a saturated monocyclic 4-7 membered heterocycle; or NR5R6, R4 and A form a saturated 4-7 membered monocyclic heterocycle; or R4,together with R7 or R8 and A and E form a 4-7 membered saturated monocyclic heterocycle; or NR5R6 and R7 or R8 together with A and E form a 4-7 membered saturated monocyclic heterocycle; and R10 is optionally substituted phenyl or benzyl.